Article

Treating postprandial hyperglycemia does not appear to delay progression of early type 2 diabetes: the Early Diabetes Intervention Program.

Indiana University School of Medicine, 545 Barnhill Dr., EH 421, Indianapolis, IN 46202, USA.
Diabetes Care (Impact Factor: 8.57). 10/2006; 29(9):2095-101. DOI: 10.2337/dc06-0061
Source: PubMed

ABSTRACT Postprandial hyperglycemia characterizes early type 2 diabetes. We investigated whether ameliorating postprandial hyperglycemia with acarbose would prevent or delay progression of diabetes, defined as progression to frank fasting hyperglycemia, in subjects with early diabetes (fasting plasma glucose [FPG] <140 mg/dl and 2-h plasma glucose > or =200 mg/dl).
Two hundred nineteen subjects with early diabetes were randomly assigned to 100 mg acarbose t.i.d. or identical placebo and followed for 5 years or until they reached the primary outcome (two consecutive quarterly FPG measurements of > or =140 mg/dl). Secondary outcomes included measures of glycemia (meal tolerance tests, HbA(1c), annual oral glucose tolerance tests [OGTTs]), measures of insulin resistance (homeostasis model assessment [HOMA] of insulin resistance and insulin sensitivity index from hyperglycemic clamps), and secondary measures of beta-cell function (HOMA-beta, early- and late-phase insulin secretion, and proinsulin-to-insulin ratio).
Acarbose significantly reduced postprandial hyperglycemia. However, there was no difference in the cumulative rate of frank fasting hyperglycemia (29% with acarbose and 34% with placebo; P = 0.65 for survival analysis). There were no significant differences between groups in OGTT values, measures of insulin resistance, or secondary measures of beta-cell function. In a post hoc analysis of subjects with initial FPG <126 mg/dl, acarbose reduced the rate of development of FPG > or =126 mg/dl (27 vs. 50%; P = 0.04).
Ameliorating postprandial hyperglycemia did not appear to delay progression of early type 2 diabetes. Factors other than postprandial hyperglycemia may be greater determinants of progression of diabetes. Alternatively, once FPG exceeds 126 mg/dl, beta-cell failure may no longer be remediable.

0 Followers
 · 
161 Views
  • [Show abstract] [Hide abstract]
    ABSTRACT: This Commentary briefly reviews the background of prediabetes including its definition and pathophysiology and describes as well the natural course of glycemic deterioration as it follows a continuum. Research efforts in identifying glucose and other biomarkers for the early detection of high-risk individuals are summarized.
    Diabetes/Metabolism Research and Reviews 11/2014; 30(8). DOI:10.1002/dmrr.2563 · 3.59 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Background The ability of interventions to affect declining β-cell function in screen-detected type 2 diabetes are poorly described. The Early Diabetes Intervention Program (EDIP; ClinicalTrials.gov NCT01470937) was a randomized study based on the hypothesis that improving postprandial glucose excursions with acarbose would slow the progression of fasting hyperglycemia in screen-detected type 2 diabetes. In EDIP, the effect of acarbose plus lifestyle advice on progression of fasting hyperglycemia over a 5 year period was not greater than that of placebo. However, there was an early glucose lowering effect of the trial. The objective of the current secondary analysis was to describe ß-cell function changes in response to glucose-lowering.Methods Participants were overweight adult subjects with screen-detected type 2 diabetes. ß-cell function was measured using hyperglycemic clamps and oral glucose tolerance testing. The primary outcome was the change in ß-cell function from baseline to Year 1, the time point where the maximal glucose-lowering effect was seen.ResultsAt baseline, participants exhibited markedly impaired first-phase insulin response. Despite significant reductions in weight, FPG, and 2-hr PG, there was no clinically significant improvement in first-phase insulin response. Late-phase insulin responses declined despite beneficial glycemic effects of interventions.Conclusions Insulin secretion is already severely impaired in early, screen-detected type 2 diabetes. Effective glucose-lowering intervention with acarbose was not sufficient to improve insulin secretion or halt the decline of β-cell function. This article is protected by copyright. All rights reserved.
    Diabetes/Metabolism Research and Reviews 11/2014; 30(8). DOI:10.1002/dmrr.2553 · 3.59 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Insulin injected directly into skeletal muscle diffuses rapidly through the interstitial space to cause glucose uptake, but this is blocked in insulin resistance. As glucotoxicity is associated with endothelial dysfunction, the observed hyperglycemia in diet-induced obese dogs may inhibit insulin access to muscle cells, and exacerbate insulin resistance. Here we asked whether interstitial insulin diffusion is reduced in modest hyperglycemia, similar to that induced by a high fat diet.Methods During normoglycemic (100 mg/dl) and moderately hyperglycemic (120 mg/dl) clamps in anesthetized canines, sequential doses of insulin were injected into the vastus medialis of one hindlimb; the contra-lateral limb served as a control. Plasma samples were collected and analyzed for insulin content. Lymph vessels of the hind leg were also catheterized, and lymph samples were analyzed as an indicator of interstitial insulin concentration.ResultsInsulin injection increased lymph insulin in normoglycemic animals, but not in hyperglycemic animals. Muscle glucose uptake was elevated in response to hyperglycemia, however the insulin-mediated glucose uptake in normoglycemic controls was not observed in hyperglycemia. Modest hyperglycemia prevented intra-muscularly injected insulin from diffusing through the interstitial space reduced insulin-mediated glucose uptake.Conclusion Hyperglycemia prevents the appearance of injected insulin in the interstitial space, thus reducing insulin action on skeletal muscle cells.
    Metabolism 11/2014; 64(2). DOI:10.1016/j.metabol.2014.10.036 · 3.61 Impact Factor